Grant of Interim Extension of the Term of U.S. Patent No. 5,912,231; LOCILEX® (pexiganan), 24307 [2017-10964]

Download as PDF Federal Register / Vol. 82, No. 101 / Friday, May 26, 2017 / Notices New England Fishery Management Council; telephone: (978) 465–0492. SUPPLEMENTARY INFORMATION: Agenda The Committee will review Plan Development Team (PDT) analysis regarding skate bait possession limits. They will discuss and select preferred alternatives for Framework 4 to the Skate Fishery Management Plan which modifies skate bait possession limits and associated measures. The committee will also review and discuss PDT analysis, to date, regarding the upcoming specifications framework which would set specifications for FYs 2018 and 2019 and would remove the prohibition on landing barndoor skates. Other business, as necessary. Although other non-emergency issues not on the agenda may come before this group for discussion, those issues may not be the subject of formal action during this meeting. Actions will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under § 305(c) of the Magnuson-Stevens Fishery Conservation and Management Act, provided the public has been notified of the Council’s intent to take final action to address the emergency. Special Accommodations This meeting is physically accessible to people with disabilities. This meeting will be recorded. Consistent with 16 U.S.C. 1852, a copy of the recording is available upon request. Requests for sign language interpretation or other auxiliary aids should be directed to Thomas A. Nies, Executive Director, at (978) 465–0492, at least 5 days prior to the meeting date. Authority: 16 U.S.C. 1801 et seq. Dated: May 22, 2017. Tracey L. Thompson, Acting Deputy Director, Office of Sustainable Fisheries, National Marine Fisheries Service. [FR Doc. 2017–10778 Filed 5–25–17; 8:45 am] BILLING CODE 3510–22–P DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No.: PTO–P–2017–0023] Grant of Interim Extension of the Term of U.S. Patent No. 5,912,231; LOCILEX® (pexiganan) United States Patent and Trademark Office, Commerce. ACTION: Notice of Interim patent term extension. AGENCY: VerDate Sep<11>2014 19:14 May 25, 2017 Jkt 241001 The United States Patent and Trademark Office has issued an order granting interim extension for a oneyear interim extension of the term of U.S. Patent No. 5,912,231. SUMMARY: FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 272– 7755; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313– 1450; by fax marked to her attention at (571) 273–7755; or by email to Mary.Till@uspto.gov. Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On May 9, 2017, Scripps Research Institute, the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for a second interim extension of the term of U.S. Patent No. 5,912,231. The patent claims a composition of the active ingredient pexiganan of the human drug product LOCILEX®. The application for patent term extension indicates that New Drug Application (NDA) 29–930 was submitted to the Food and Drug Administration (FDA) on July 24, 1998. Review of the patent term extension application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory review period will continue beyond the extended expiration date of the patent, June 15, 2017, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 5,912,231 is granted for a period of one year from the extended expiration date of the patent. SUPPLEMENTARY INFORMATION: Dated: May 22, 2017. Robert Bahr, Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office. [FR Doc. 2017–10964 Filed 5–25–17; 8:45 am] BILLING CODE 3510–16–P PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 24307 DEPARTMENT OF COMMERCE Patent and Trademark Office Submission for OMB Review; Comment Request; Trademark Trial and Appeal Board (TTAB) Actions The United States Patent and Trademark Office (USPTO) will submit to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35). Agency: United States Patent and Trademark Office, Commerce Title: Trademark Trial and Appeal Board (TTAB) Actions OMB Control Number: 0651–0040. Form Number(s): • PTO 2120 • PTO 2151 • PTO 2153 • PTO 2188 • PTO 2189 • PTO 2190 Type of Request: Revision of a currently approved collection. Number of Respondents: 78,000 per year. Average Hours per Response: Between 10 minutes (0.17 hours) and 30 minutes (0.5 hours) to gather the necessary information, prepare the materials, and to submit it to the USPTO, depending upon the instrument used. Burden Hours: 15,997.67 hours. Cost Burden: $5,744,000.00. Needs and Uses: This information is required by the Trademark Act of 1946, Sections 13, 14, and 20, 15 U.S.C. 1063, 1064, and 1070, respectively. The information in this collection is a matter of public record and is used by the public for a variety of private business purposes related to establishing and enforcing trademark rights. This information is important to the public, as both common law trademark owners and Federal trademark registrants must actively protect their own rights. This collection includes the information needed by the USPTO to review the various types of petitions to cancel the registration of a mark, notices of opposition to the registration of a mark, extensions of time to file an opposition, appeals, and other papers filed in connection with inter partes and ex parte proceedings. Affected Public: Businesses or other for-profits; not-for-profit institutions. Frequency: On occasion. Respondent’s Obligation: Required to Obtain or Retain Benefits. OMB Desk Officer: Nicholas A. Fraser, email: Nicholas_A._Fraser@ omb.eop.gov. Once submitted, the E:\FR\FM\26MYN1.SGM 26MYN1

Agencies

[Federal Register Volume 82, Number 101 (Friday, May 26, 2017)]
[Notices]
[Page 24307]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10964]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

 Patent and Trademark Office

[Docket No.: PTO-P-2017-0023]


Grant of Interim Extension of the Term of U.S. Patent No. 
5,912,231; LOCILEX[supreg] (pexiganan)

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of Interim patent term extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting interim extension for a one-year interim extension of 
the term of U.S. Patent No. 5,912,231.

FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 
272-7755; by mail marked to her attention and addressed to the 
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, 
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to one year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On May 9, 2017, Scripps Research Institute, the patent owner of 
record, timely filed an application under 35 U.S.C. 156(d)(5) for a 
second interim extension of the term of U.S. Patent No. 5,912,231. The 
patent claims a composition of the active ingredient pexiganan of the 
human drug product LOCILEX[supreg]. The application for patent term 
extension indicates that New Drug Application (NDA) 29-930 was 
submitted to the Food and Drug Administration (FDA) on July 24, 1998.
    Review of the patent term extension application indicates that, 
except for permission to market or use the product commercially, the 
subject patent would be eligible for an extension of the patent term 
under 35 U.S.C. 156, and that the patent should be extended for one 
year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory 
review period will continue beyond the extended expiration date of the 
patent, June 15, 2017, interim extension of the patent term under 35 
U.S.C. 156(d)(5) is appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 5,912,231 is granted for a period of one year from the 
extended expiration date of the patent.

    Dated: May 22, 2017.
Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent 
and Trademark Office.
[FR Doc. 2017-10964 Filed 5-25-17; 8:45 am]
 BILLING CODE 3510-16-P